Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sucampo Pharmaceuticals Inc Announces Positive Top-Line Results in Phase 1a Trials of Cobiprostone and SPI-3608

Wednesday, 7 Aug 2013 08:02pm EDT 

Sucampo Pharmaceuticals Inc announced the positive top-line results of two recently completed clinical trials, a Phase 1a trial of cobiprostone and a Phase 1a trial of SPI-3608. The studies tested the tolerability and pharmacokinetic profiles versus placebo of the two compounds, both of which were demonstrated to be generally well-tolerated in the tested populations. 

Company Quote

23 Jan 2015